The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
Treatment of restless legs syndrome: An evidence‐based review and implications for clinical practice
Open accessAbstract
Only in the last three decades, the restless legs syndrome (RLS) has been examined in randomized controlled trials. The Movement Disorder Society (MDS) commissioned a task force to perform an evidence‐based review of the medical literature on treatment modalities used to manage patients with RLS. The task force performed a search of the published literature using electronic databases. The therapeutic efficacy of each drug was classified as being either efficacious, likely efficacious, investigational, nonefficacious, or lacking sufficient evidence to classify. Implications for clinical practice were generated based on the levels of evidence and particular features of each modality, such as adverse events. All studies were classed according to three levels of evidence. All Level‐I trials were included in the efficacy tables; if no Level‐I trials were available then Level‐II trials were included or, in the absence of Level‐II trials, Level‐III studies or case series were included. Only studies published in print or online before December 31, 2006 were included. All studies published after 1996, which attempted to assess RLS augmentation, were reviewed in a separate section. The following drugs are considered efficacious for the treatment of RLS: levodopa, ropinirole, pramipexole, cabergoline, pergolide, and gabapentin. Drugs considered likely efficacious are rotigotine, bromocriptine, oxycodone, carbamazepine, valproic acid, and clonidine. Drugs that are considered investigational are dihydroergocriptine, lisuride, methadone, tramadol, clonazepam, zolpidem, amantadine, and topiramate. Magnesium, folic acid, and exercise are also considered to be investigational. Sumanirole is nonefficacious. Intravenous iron dextran is likely efficacious for the treatment of RLS secondary to end‐stage renal disease and investigational in RLS subjects with normal renal function. The efficacy of oral iron is considered investigational; however, its efficacy appears to depend on the iron status of subjects. Cabergoline and pergolide (and possibly lisuride) require special monitoring due to fibrotic complications including cardiac valvulopathy. Special monitoring is required for several other medications based on clinical concerns: opioids (including, but not limited to, oxycodone, methadone and tramadol), due to possible addiction and respiratory depression, and some anticonvulsants (particularly, carbamazepine and valproic acid), due to systemic toxicities. © 2008 Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Evidence-Based Medicine: How to Practice and Teach EBM
Sackett, D. L. (2000) · Cited by 5,950
Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology
Allen, R. P., Picchietti, D., Hening, W. A., Trenkwalder, C., Walters, A. S., & Montplaisi, J. (2003) · Sleep Medicine · doi:10.1016/s1389-9457(03)00010-8 · Cited by 2,900
Self-citationSystematic Reviews: Identifying relevant studies for systematic reviews
Dickersin, K., Scherer, R., & Lefebvre, C. (1994) · BMJ · doi:10.1136/bmj.309.6964.1286 · Cited by 2,256
Evidence-Based Medicine: How to Practice and Teach EBM
Satya-Murti, S. (2000) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.284.18.2382 · Cited by 1,643
Valvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease
Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S., & Pezzoli, G. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa054830 · Cited by 884
Publication bias: evidence of delayed publication in a cohort study of clinical research projects
Stern, J. M., & Simes, R. J. (1997) · BMJ · doi:10.1136/bmj.315.7109.640 · Cited by 818
Winkelmann, J., Schormair, B., Lichtner, P., Ripke, S., Xiong, L., Jalilzadeh, S., Fulda, S., Pütz, B., Eckstein, G., Hauk, S., et al. (2007) · Nature Genetics · doi:10.1038/ng2099 · Cited by 704
Self-citationA Genetic Risk Factor for Periodic Limb Movements in Sleep
Stefansson, H., Rye, D. B., Hicks, A., Petursson, H., Ingason, A., Thorgeirsson, T. E., Palsson, S., Sigmundsson, T., Sigurdsson, A. P., Eiriksdottir, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072743 · Cited by 630
Grégoire, G., Derderian, F., & Le Lorier, J. (1995) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)00098-b · Cited by 526
Cited by
Earley, C. J., Connor, J., Garcia-Borreguero, D., Jenner, P., Winkelman, J., Zee, P. C., & Allen, R. (2014) · Sleep Medicine · doi:10.1016/j.sleep.2014.05.009 · Cited by 336
Self-citationRestless legs syndrome: pathophysiology, clinical presentation and management
Trenkwalder, C., & Paulus, W. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.55 · Cited by 310
Self-citationGarcia-Borreguero, D., Kohnen, R., Silber, M. H., Winkelman, J. W., Earley, C. J., Högl, B., Manconi, M., Montplaisir, J., Inoue, Y., & Allen, R. P. (2013) · Sleep Medicine · doi:10.1016/j.sleep.2013.05.016 · Cited by 291
Self-citationComorbidities, treatment, and pathophysiology in restless legs syndrome
Trenkwalder, C., Allen, R., Högl, B., Clemens, S., Patton, S., Schormair, B., & Winkelmann, J. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30311-9 · Cited by 275
Self-citationTreatment of hyperkinetic movement disorders
Jankovic, J. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70183-8 · Cited by 252
Innes, K. E., & Selfe, T. K. (2012) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2012/294058 · Cited by 79
Metadata
- Authors
- Trenkwalder, C., Hening, W. A., Montagna, P., Oertel, W. H., Allen, R. P., Walters, A. S., Costa, J., Stiasny‐Kolster, K., & Sampaio, C.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2008-10-16
- Volume
- 23
- Issue
- 16
- Pages
- 2267-2302
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2085792179
- Cited by
- 264
- References
- 93
- FWCI
- 22.99
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.